No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine

M. Van VugtF. EzzetF. NostenI. GathmannP. WilairatanaS. LooareesuwanN. J. WhiteShoklo Malaria Research UnitAcademic Medical Centre, University of AmsterdamNovartis International AGJohn Radcliffe HospitalMahidol University2018-09-072018-09-071999-01-01American Journal of Tropical Medicine and Hygiene. Vol.61, No.6 (1999), 964-967000296372-s2.0-0033386669https://repository.li.mahidol.ac.th/handle/20.500.14594/25476Artemether-lumefantrine is a new fixed antimalarial combination effective against multidrug-resistant falciparum malaria. A prospective electrocardiographic study was conducted in 150 patients receiving artemether-lumefantrine and 50 treated with artesunate-mefloquine. There was no evidence for clinically significant changes in the electrocardiographic intervals and in particular no relationship between plasma concentrations of lumefantrine and QTc prolongation. Artemether-lumefantrine does not have significant cardiac effects at therapeutic doses.Mahidol UniversityImmunology and MicrobiologyMedicineNo evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrineArticleSCOPUS10.4269/ajtmh.1999.61.964